{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.0"},{"groupId":"OG001","value":"77.0"}]}],"title":"Nurse: Rituximab SC is much more convenient"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0"},{"groupId":"OG001","value":"9.0"}]}],"title":"Nurse: Rituximab SC is a little more convenient"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.0"},{"groupId":"OG001","value":"4.0"}]}],"title":"Nurse: Both formulations are equally convenient"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0"},{"groupId":"OG001","value":"10.0"}]}],"title":"Nurse: Rituximab IV is a little more convenient"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}],"title":"Nurse: Rituximab IV is much more convenient"},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.0"},{"groupId":"OG001","value":"80.0"}]}],"title":"Physician: Rituximab SC is much more convenient"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.0"},{"groupId":"OG001","value":"14.0"}]}],"title":"Physician: Rituximab SC a little more convenient"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0"},{"groupId":"OG001","value":"6.0"}]}],"title":"Physician: Both formulations equally convenient"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}],"title":"Physician: Rituximab IV a little more convenient"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}],"title":"Physician: Rituximab IV is much more convenient"}],"denoms":[{"counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"81"}],"units":"Participants"}],"description":"Physicians and nurses who administered rituximab were asked to answer the following question: \"Which formulation of rituximab (SC or IV) do you think is more convenient?\" with pre-specified responses as below. Percentage of participants with specified answers were reported. The number of nurses that responded for both the IV and SC arms was 70. The number of physicians that responded for the IV and SC arms were 78 and 81 respectively.","groups":[{"description":"Participants received the following in 28-day cycles. Cycle 1: IV rituximab 375 mg/m\\^2 on Day 0 Cycles 2-6: IV rituximab 500 mg/m\\^2 on Day 1 Cycles 1-6: IV fludarabine 25 mg/m\\^2 on Days 1-3 (or as an oral dose of 24 mg/m\\^2 on Days 1-5 or 30-40 mg/m\\^2 on Days 1-3), and IV cyclophosphamide 250 mg/m\\^2 on Days 1-3 (or as an oral dose of 150 mg/m\\^2 on Days 1-5 or 200-250 mg/m\\^2 on Days 1-3).","id":"OG000","title":"Part 2 : Rituximab IV 500 mg/m^2"},{"description":"Participants received the following in 28-day cycles. Cycle 1: IV rituximab 375 mg/m\\^2 on Day 0 Cycles 2-6: SC rituximab 1600 mg on Day 1 Cycles 1-6: IV fludarabine 25 mg/m\\^2 on Days 1-3 (or as an oral dose of 24 mg/m\\^2 on Days 1-5 or 30-40 mg/m\\^2 on Days 1-3), and IV cyclophosphamide 250 mg/m\\^2 on Days 1-3 (or as an oral dose of 150 mg/m\\^2 on Days 1-5 or 200-250 mg/m\\^2 on Days 1-3).","id":"OG001","title":"Part 2: Rituximab SC 1600 mg"}],"paramType":"NUMBER","populationDescription":"All the physicians and nurses who responded to the questionnaire were included in the analysis.","reportingStatus":"POSTED","timeFrame":"Days 4-5 in Cycle 6","title":"Part 2: Physician/Nurse Opinion on Convenience of Rituximab SC Compared With Rituximab IV","type":"SECONDARY","unitOfMeasure":"percentage of participants in the survey"}